Streetbeat News

Products Services

CHRS

Coherus has lowered its 2023 guidance for combined R&D and SG&A expenses from $315M-$335M to $300M-$310M. It has also reduced its 2023 net product revenue guidance to $250M-$260M from an estimated $288.19M. This is primarily due to the delay in the commercial launches of UDENYCA® On-body Injector and LOQTORZI™.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 10:42 pm

GILD

RCUS

Gilead Sciences, Inc. (GILD) and Arcus Biosciences, Inc. (RCUS) have reported new data showing encouraging clinical activity of anti-TIGIT Domvanalimab-containing regimen as a first-line treatment for upper gastrointestinal (GI) cancers.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 10:40 pm

THAR

Tharimmune has entered into an exclusive global licensing agreement for a clinical stage asset for chronic pruritis. The company expects to complete a Phase 2 clinical trial and release topline data approximately 12 months after aligning with the FDA on trial design.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 10:38 pm

MASS

908 Devices and Terumo Blood and Cell Technologies are collaborating to add on-line analytics to the Quantum Flex Cell Expansion System. The aim is to increase manufacturing efficiencies and patient accessibility and safety in cell therapy.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 10:36 pm

BLDP

Ballard Power Systems has announced orders for 62 hydrogen fuel cell engines to power Solaris buses in Europe. The majority of the fuel cell engines are expected to be delivered in 2024. Financial terms of the deal were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 10:32 pm

IVA

Inventiva (NASDAQ:IVA) has announced that its lead compound, Lanifibranor, will be the subject of a late breaker abstract and two additional abstracts at the AASLD The Liver Meeting 2023. The abstracts will present results from phase II trials evaluating Lanifibranor in patients with T2D and MASLD, and patients with NASH. The results show a correlation between the increase of adiponectin under Lanifibranor and the improvement of histological and serum markers of NASH severity. The efficacy of Lanifibranor appears to be independent of PNPLA3 status.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 10:30 pm

VTYX

Ventyx Biosciences announced that the Phase 2 trial of VTX958 in plaque psoriasis did not meet the internal target, which does not support further development of VTX958 in psoriasis. This has led to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:58 pm

SNTI

Senti Biosciences (NASDAQ:SNTI) has announced a strategic collaboration with China-based biotech company Celest Therapeutics for the clinical development of SENTI-301A, a therapy for solid tumors, in China. Celest will lead clinical development, operations, and manufacturing with technical support from Senti Bio. The first patient is expected to be enrolled in China in 1H 2024. Senti Bio could receive up to $156 million in milestone payments and potential tiered royalty payments. Senti Bio retains all commercialization rights outside of mainland China, Hong Kong, Macau, and Taiwan for SENTI-301A.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:41 pm

DKNG

A sports bettor won a $50,000 windfall on a 1,000-to-1 bet placed with DraftKings Inc (NASDAQ:DKNG) on the performance of Boston Celtics' backup point guard Payton Pritchard in a recent NBA game. The bettor wagered on Pritchard to achieve certain stats and the Celtics to win by a certain margin, all of which occurred. The Celtics are currently the favorite to win the 2023-2024 NBA Championship.

Portfolio Pulse from Chris Katje

November 06, 2023 | 9:36 pm

TFX

The FDA has identified a Class I recall of pressure injectable catheter kits due to mislabeling. The recall involves products from Teleflex and Arrow International.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:24 pm